8-K: BioCardia Reports Full Year 2023 Results, Advances Clinical Programs

BioCardia announced its 2023 financial results and provided updates on its clinical programs, including positive subgroup data from its CardiAMP Heart Failure trial.

Summary

• BioCardia reported a net loss of $11.6 million for 2023, compared to a $11.9 million loss in 2022.
• Revenue decreased to $0.5 million in 2023 from $1.4 million in 2022, primarily due to the timing of revenue from collaborative partners.
• Research and development expenses decreased to $7.7 million in 2023 from $8.8 million in 2022 due to the completion of enrollment in the CardiAMP Heart Failure Trial.
• The company's cash and cash equivalents totaled $1.1 million at the end of 2023, with additional financing secured in the first quarter of 2024 to provide runway into the second quarter of 2024.
• Interim results from the CardiAMP Heart Failure trial showed a 37% relative risk reduction in heart death equivalents and a 9% reduction in non-fatal major adverse cardiac events in treated patients.
• A subgroup analysis of patients with elevated NTproBNP showed an 86.2% relative risk reduction in heart death equivalents and a 23.9% relative risk reduction in MACCE.
• The company plans to complete follow-up for the CardiAMP Heart Failure trial in the fourth quarter of 2024 and submit data for potential approval in Japan.
• The CardiAMP Heart Failure II trial, a confirmatory Phase III study, was activated in the first quarter of 2024 and has Medicare reimbursement.
• The company expects FDA approval for its Morph DNA steerable sheath introducers in the third quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results. While there are positive clinical trial outcomes, the financial results are weak, and the company's cash position is concerning. The sentiment is neutral to slightly negative due to the financial challenges.

Positives

• The CardiAMP Heart Failure trial showed significant risk reductions in heart death equivalents and major adverse cardiac events in treated patients.
• The subgroup analysis of patients with elevated NTproBNP showed even more substantial risk reductions.
• The CardiAMP Heart Failure II trial has been activated and has Medicare reimbursement, reducing clinical costs.
• The company is progressing its Morph Access Innovations business with expected FDA approval in the third quarter of 2024.
• BioCardia has secured a new biotherapeutic delivery partnership with StemCardia and expects two more in 2024.
• The company is exploring partnerships for its CardiAMP therapy for other clinical indications.

Negatives

• BioCardia's revenue decreased significantly in 2023 compared to 2022.
• The company reported a net loss of $11.6 million for 2023.
• The company's cash and cash equivalents are low at $1.1 million, requiring additional financing to continue operations.
• The CardiAMP Heart Failure trial missed its primary endpoint as designed, although subgroup analysis showed positive results.

Risks

• The company's low cash balance poses a risk to its ability to continue operations without additional funding.
• The company faces risks associated with developing new products and technologies, including regulatory approvals and unexpected expenditures.
• The company may find it difficult to enroll patients in clinical trials, which could delay development.
• The company's reliance on partnerships for revenue and development creates a risk if these partnerships are not successful.
• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

BioCardia aims to complete the CardiAMP Heart Failure trial follow-up, seek approval in Japan, advance the CardiAMP Heart Failure II trial, and progress earlier biotherapeutic product candidates. They also intend to secure value from their Helix and Morph businesses and expect two additional premier biotherapeutic delivery partnerships in 2024.

Management Comments

• Heart failure of reduced ejection fraction or HFrEF remains an unmet clinical need with none of the recently approved therapies reducing mortality, said BioCardia CEO Peter Altman, Ph.D.
• The interim data from our CardiAMP Heart Failure trial, where we missed the primary endpoint, shows reduced heart death equivalents, reduced major adverse cardiac events, reduced cardiac arrhythmias, and enhanced heart function in treated patients relative to the control patients.
• In 2024, we aim to complete the study follow-up, seek approval in Japan, and advance the confirmatory CardiAMP Heart Failure II Trial.

Industry Context

The announcement highlights BioCardia's efforts in the competitive field of cardiovascular therapeutics, particularly in addressing heart failure, where there is a significant unmet need. The company's focus on cell therapies and biotherapeutic delivery systems aligns with broader trends in regenerative medicine and targeted drug delivery.

Comparison to Industry Standards

• The 37% relative risk reduction in heart death equivalents in the CardiAMP trial is a notable result, although the trial missed its primary endpoint. This result is comparable to some other cell therapy trials in heart failure, but the subgroup analysis showing an 86.2% reduction is particularly promising.
• Companies like Mesoblast and Athersys are also developing cell therapies for cardiovascular diseases, and BioCardia's results will be closely watched in comparison to their clinical trial outcomes.
• The development of the Morph DNA steerable sheath introducers is a unique approach to improving delivery of therapies, and its success will be compared to other delivery systems in the market.

Stakeholder Impact

• Shareholders may be concerned about the company's financial performance and low cash balance.
• Employees may be impacted by the company's financial situation and potential need for cost-cutting measures.
• Patients may benefit from the company's clinical programs if they are successful.
• Partners may be impacted by the company's financial situation and ability to execute on partnerships.

Next Steps

• Complete follow-up in the CardiAMP Heart Failure trial in the fourth quarter of 2024.
• Submit clinical data to Japan's Pharmaceutical and Medical Device Agency in the fourth quarter of 2024.
• Initiate the randomized cohort in the pivotal CardiAMP CMI Trial in the third quarter of 2024.
• Complete the low-dose cohort of the CardiALLO trial in the second quarter of 2024.
• Complete the medium-dose cohort of the CardiALLO trial in the fourth quarter of 2024.
• Secure a third revenue sharing partnership agreement in the second quarter of 2024.
• Obtain FDA approval for the Morph DNA steerable introducer sheath product family in the third quarter of 2024.

Key Dates

Keywords

BioCardia, CardiAMP, Heart Failure, Cell Therapy, Clinical Trial, Biotherapeutic Delivery, Morph DNA, Cardiovascular Disease, HFrEF, FDA, Medicare, Partnership